Aclaris Therapeutics, Inc.
ACRS
$3.59
$0.298.79%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -85.94% | -24.09% | -35.76% | -39.32% | -47.58% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -85.94% | -24.09% | -35.76% | -39.32% | -47.58% |
| Cost of Revenue | 3.85% | 100.46% | 24.66% | 12.11% | -33.50% |
| Gross Profit | -76.98% | -287.49% | -45.81% | -25.39% | 14.88% |
| SG&A Expenses | 12.56% | -13.83% | 13.34% | -10.30% | -32.27% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 1.49% | 45.17% | 21.17% | 3.83% | -39.01% |
| Operating Income | -58.73% | -76.29% | -33.62% | -10.25% | 31.70% |
| Income Before Tax | 79.50% | -92.64% | -40.44% | 10.96% | -5,096.56% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 79.50% | -92.64% | -40.44% | 10.96% | -6,375.65% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 79.50% | -92.64% | -40.44% | 10.96% | -6,375.65% |
| EBIT | -58.73% | -76.29% | -33.62% | -10.25% | 31.70% |
| EBITDA | -59.15% | -77.64% | -33.84% | -11.06% | 31.48% |
| EPS Basic | 84.07% | -12.14% | 18.30% | 48.28% | -4,724.29% |
| Normalized Basic EPS | -37.60% | -24.58% | 24.95% | 39.26% | 55.79% |
| EPS Diluted | 84.07% | -12.14% | 18.30% | 48.28% | -4,724.29% |
| Normalized Diluted EPS | -37.60% | -24.58% | 24.95% | 39.26% | 55.79% |
| Average Basic Shares Outstanding | 28.71% | 71.78% | 71.94% | 72.20% | 34.49% |
| Average Diluted Shares Outstanding | 28.71% | 71.78% | 71.94% | 72.20% | 34.49% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |